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Leucine-rich repeat kinase 2 (LRRK2) is a large 286 kDa multi-
domain protein whose mutation is a common cause of 
Parkinson's disease (PD). One of the common sites of familial 
PD-associated mutations occurs at residue Arg-1441 in the 
GTPase domain of LRRK2. Previously, we reported that the PD-
associated mutation R1441H impairs the catalytic activity of 
the GTPase domain thereby traps it in a persistently "on" state. 
More recently, we reported that the GTPase domain of LRRK2 
exists in a dynamic dimer-monomer equilibrium where GTP 
binding shifts it to the monomeric conformation while GDP 
binding shifts it back to the dimeric state. We also reported that 
all of the PD-associated mutations at Arg-1441, including 
R1441H, R1441C, and R1441G, impair the nucleotide-
dependent dimer-monomer conformational dynamics of the 
GTPase domain. However, the mechanism of this nucleotide-
dependent conformational dynamics and how it is impaired by 
the mutations at residue Arg-1441 remained unclear. Here, we 
report a 1.6 Å crystal structure of the GTPase domain of LRRK2. 
Our structure has revealed a dynamic switch region that can be 
differentially regulated by GTP and GDP binding.  This 
nucleotide-dependent regulation is impaired when residue Arg-
1441 is substituted with the PD-associated mutations due to 
the loss of its exquisite interactions consisting of two hydrogen 
bonds and a π-stacking interaction at the dimer interface.  
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Abbreviations: LRRK2, Leucine-Rich Repeat Kinase 2; ROC, Ras of complex 
proteins; COR, C-terminal of ROC 
 
Significance Statement 
Mutations in LRRK2 are associated with familial Parkinson's 
disease, so understanding its mechanism of actions and how they 
are changed by the disease-associated mutations is important for 
developing therapeutic strategies. This paper describes an atomic 
structure of the G-domain of LRRK2 revealing that the 
conformational dynamics of the switch regions are potentially 
important for its normal function. It further shows that a disease-
associated mutation could lock the G domain in a persistently 





Mutation in the Leucine-Rich Repeat Kinase 2 (LRRK2) is a 
common cause of familial Parkinson's disease (PD)(1-5). LRRK2 is 
a large (2,527 amino acids) multi-domain enzyme consisting of 7                                                                                                                                                                      
putative domains(2), including a HEAT repeat, an Ankyrin repeat, a 
Leucine-rich repeat (LRR), a Ras-like GTPase domain called ‘Ras of 
complex proteins’ (ROC), a unique domain called C-terminal of 
ROC (COR), a kinase domain (Kin), and a C-terminal WD40 
repeat(6). The most common PD-associated mutations (G2019S and 
R1441G/C/H) are found in the central three domains, ROC-COR-
Kin, that constitutes the catalytic core of the protein. Residue Gly-
2019 is predicted to reside in the activation loop of the kinase 
domain, and the G2019S mutant has been shown to have higher 
kinase activity than that of the wild-type enzyme(7, 8). Thus, the 
glycine to serine substitution mutation, which introduces a hydroxyl 
group, potentially mimics the activated state of the kinase. 
 The effects of the PD-associated mutations in the ROC domain at 
residue Arg-1441 (R1441G/C/H) have been less understood. Several 
studies have shown that GTP binding to the ROC domain up 
regulates LRRK2 kinase activity(9, 10) and, conversely, inhibition 
of ROC decreases kinase activity(9-13), thus indicating that the 
ROC domain could modulate the activity of the kinase domain. 
Moreover, the PD-associated mutations at Arg-1441 have been 
shown to also result in a higher LRRK2 kinase activity than that of 
the wild-type(8, 9, 12), suggesting that residue Arg-1441 is vital for 
the normal functioning of ROC.  Indeed, we recently engineered a 
stable construct of ROC (ROCext) and showed that the R1441H 
mutation perturbs the hydrolytic conversion of GTP to GDP, thereby 
prolonging the GTP-bound "on" state of ROC(14). Subsequently, we 
showed that GTP-binding drives dimeric ROCext disassembly into 
monomers and GDP-binding oppositely shifts the equilibrium back 
to dimers(15). Moreover, we showed that all the PD-associated 
mutations at Arg-1441, as well as N1437H, impair the dimer-
monomer dynamics of ROCext(15, 16). 
 The mystery remains as to how residue Arg-1441 affects the 
catalytic activity of ROC and its nucleotide-dependent 
conformational dynamics given that the position 1441 resides 
outside of the regions known to be involved in the activity of 
GTPases, including the nucleotide-binding site, active-site, and the 
switch regions. Here, we show a high-resolution crystal structure of 
ROCext revealing the role of residue R1441 in the stability of the 
dimeric conformation and providing insights into how the 
Parkinson's disease-associated mutations R1441G/C/H impair its 
conformational dynamics.  
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Figure 1. Structure of ROCext. a) Crystal structure of ROC dimer (1.6 A) shown in semi-transparent surface and ribbon presentations. 
Chain A is colored orange and chain B colored teal. The dotted lines outline the areas presented in b) and c). b) Enlarged view of the area 
highlighted in top panel of a) showing extensive hydrogen bonding at the dimer interface. c) Enlarged view of the area highlighted in bottom 
panel of a) showing a hydrophobic patch at the dimer interface, which is capped at both ends by residue R1441. d) and e) ribbon 
presentation showing signature structural features of a small GTPase, including Switch I (magenta), InterSwitch (blue), and Switch II (teal). 
GDP is shown as rod-and-ball model. f) and g) electron-density map (2FoFc) of the Switch regions and GDP, respectively, contoured at 1.0 
σ.  
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Results and Discussion 
 
The architecture of the ROC domain of LRRK2  
 While a structure of the ROC domain of LRRK2 has been 
determined a decade ago (PDB ID: 2ZEJ)(17), that structure has 
been inconsistent with subsequent biochemical and biophysical 
observations. For example, the 2ZEJ structure showed an obligate 
dimer with an active-site composed of one half from each protomer; 
however, biochemical studies have demonstrated that ROC 
dynamically interconverts between its dimeric and monomeric 
conformations and that the monomers are catalytically active(14, 
15). Thus, the examination of the 2ZEJ structure did not provide us 
with the insights that we sought to understand the conformational 
dynamics ROC and the mechanisms of the PD-associated mutations. 
We attempted to glean these insights from structures of the 
homologous protein Roco from C. tepidum(18, 19); however, we 
found significant differences between the ROC domain of human 
LRRK2 (HsROC) and that of C. tepidum Roco (CtROC). For 
example, the PD-associated residues in HsROC are not conserved in 
CtROC, including residue R1441 in HsROC; therefore, the potential 
biochemical and structural effects of the PD-associated mutations 
cannot be inferred directly from the CtROC structures. Due to these 
reasons, we set out to determine the structure of the human ROCext 
construct to examine the structural bases for the biochemical and 
conformational dynamics we observed(14, 15, 20). 
We have determined a crystal structure of ROCext to 1.6 Å 
resolution using X-ray crystallography. The initial electron density 
map was calculated using a combination of phases determined with 
SHARP(21) using single-wavelength anomalous dispersion of 
selenomethionine (SeM-SAD) from crystals of selenomethionine-
substituted proteins, which diffracted to 3.7 Å, and those calculated 
by the molecular replacement (MR) method using the program 
Phenix(22) with a 1.9 Å native dataset. To obtain a better crystal 
quality and higher resolution, we performed “surface engineering” 
by substituting two surface lysine residues for alanine (K1460A and 
K1463A). The surface engineered mutant (KA) retained wild-type 
activity and structure (Fig. S1). The data from crystals of the 
surface-engineered protein extended to 1.6 Å resolution and were 
used for model building and refinement. A contiguous polypeptide 
chain ranging from residues 1331 to 1518, which nearly 
encompassed the entire ROCext construct (1329-1520), was 
unambiguously fitted into the electron density and refined to 
convergence with R-factor and R-free of 14% and 16%, respectively 
(Sup. Table 1). 
 The asymmetric unit (AU) consists of a homodimeric structure of 
ROCext related by 2-fold symmetry. The interactions at the dimer 
interface are extensive, burying 6461 Å2 of surface area (Fig. 1a-c). 
The intermolecular interactions are mediated chiefly by the 
structures that are known as Switch I, Switch II, and the InterSwitch, 
herein collectively referred to as the Switch regions (Fig. 1b-e). The 
dimeric interface is unusual in that the InterSwitch is flipped open 
and inserted into its dimeric partner in trans with both monomers 
wrapped around each other like a pretzel (Fig. 1a). This dimeric 
conformation has been previously observed in M. Musculus Rab27b, 
which showed a similar extended InterSwitch structure that reaches 
across the homodimeric interface(23). Apo Rab27b exists in solution 
as a monomer with its InterSwitch extended, however, upon binding 
to its effector Slac2-a it folds into a typical G-protein conformation 
with a retracted InterSwitch and adopting a conformation similar to 
that of the typical Ras-family of G-proteins(24).  
 The tertiary structure of ROCext is very similar to other G-proteins 
in that it consists of all the characteristic structural elements, 
including Switch I, Switch II, P-loop, and the G-binding motifs (Fig. 
1d-g). The Switch I and Switch II regions of ROCext are distal from 
the GDP-binding site, as they can also occur in GDP-bound Ras-like 
GTPases. However, in contrast to Ras, the InterSwitch of ROCext, 
which is flanked by the Switch I and Switch II, is flipped outward 
and protrude away from the protein core - like a 'thumbs-up' hand 
gesture (Fig. 1d,e). A well-defined molecule of GDP is bound in a 
location similar to the nucleotide-binding site in Ras (Fig. 1g).   
 
Comparison of ROCext with the previously reported ROC structure  
 Superposition of the structure of ROCext with 2ZEJ revealed two 
significantly different structures (RMSD = 10.4 A2). A large portion 
of the N-terminus of 2ZEJ (residues 1335-1397) consisting of β1, 
H1, β2, and β3 are flipped outward and detached from the rest of the 
protein, in effect, breaking the G-domain into two distinct halves 
with the N- and C-terminus separated from each other (Fig. 2a). 
Removing the non-overlapping moieties, β1 and H1, from the 
structural superposition resulted in two structures that are nearly 
identical (RMSD = 0.4 A2). Close inspection revealed that the β1 
and H1 moieties in chain A of 2ZEJ occupy precisely the same 
locations of the β1 and H1 of chain B in our ROCext structure (Fig. 
2b), thus suggesting that the structural differences might be simply 
due to the difference in chain assignment of β1 and H1. Indeed, 
superposition of the two structures as dimers showed nearly identical 
structures (RMSD = 0.3 A2). Inspection of the electron-density map 
of the 2ZEJ structure revealed that the junctions between H1 and β2, 
where the Switch I would reside, lacked interpretable density (Fig. 
S2, S3); thus rendering the task of assigning the chain ID for the H1 
and β2 segment ambiguous. Since our electron-density map 
 
Figure 2. Superposition of ROCext with 2ZEJ. a) Structure of ROCext (gold) superimposed with the ROC 
structure in the literature, 2ZEJ, (blue). The equivalent structural elements that are located in different 
locations in the two structures are outlined with dashed lines. b) Superposition of ROCext dimer (gold and 
red) with 2ZEJ (teal and blue), showing overlap of all atomic positions of 2ZEJ with those of ROCext. 
Structural elements in ROCext missing in 2ZEJ are highlighted with grey dashed lines.  
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unambiguously defined a contiguous polypeptide chain, we propose 
that the ROCext presented herein represents a revised structural 
model. Indeed, when the chain ID assignments for β1 and Η1 in 
2ZEJ were swapped (A to B and vice versa), the resulting structure 
looked nearly identical to our ROCext (Fig. S4).  
 
Comparison of human ROC with C. tepidum Roco 
Because of the difficulty in obtaining sufficient quantity of LRRK2 
amenable for detailed investigations, insights into its structure and 
function have been inferred from the amoeba and bacterial 
homologs(18, 25). Notably, much insight into the ROC domain of 
LRRK2 (HsROC) has been inferred from a ROC structure of the 
bacterium C. tepidum Roco protein (CtROC) (PDB ID: 3DPU, 
6HLU). For example, the mechanism of GTPase hydrolysis of 
HsROC has been proposed based on the studies of CtROC, where 
the activation occurs upon an arginine finger exchange in the active-
site mediated by homodimerization (known as the GTPase 
activation by dimerization model or GAD) (18),(26). However, we 
have recently shown that ROCext is catalytically active as a 
monomer, suggesting that the mechanism of HsROC might be 
different from that of CtROC. To assess the similarity and 
differences between CtROC and ROCext, we superimposed the two 
structures. Although they share low sequence identity (25%), the 
overall architecture of the two structures are remarkably similar 
(RMSD = 2.2 Å2) (Fig. 3a). Nevertheless, the superimposed 
structures did reveal several important differences: firstly, the ROC-
ROC dimeric interface of CtROC contains the P-loop, whereas the 
dimeric interface of ROCext comprises of the Switch regions (Fig. 
3b). Note that neither the dimerization mode of CtROC nor ROCext 
supports a GAD mechanism of GTPase activation, as there is no 
arginine finger-exchange occurring in the active sites. Second, the 
disease-associated residues R1441, N1437, and R1398 in HsROC 
structurally aligned with residues Y558, H554, and Q519 of CtROC, 
respectively. The difference in amino acids at these positions is 
important in that the substitution of residue Arg1441 in HsROC for 
Tyr found in the equivalent position in CtROC, and residue N1437 
in HsROC for His of CtROC both resulted in impairment of the 
conformational dynamics of ROCext(15, 16) (Fig. 3c). Finally, the 
arginine residue R543 of CtROC that is proposed to serve as the 
GTPase-activating arginine finger is structurally equivalent to 
residue S1422 of HsROC (Fig. 3d). While the studies of CtRoco 
have been instrumental for the understanding of the overall 
architecture of ROC-COR, these structural differences suggest 
caution in deducing the structure and mechanisms of HsROC from 
the observations of CtROC. 
 
The crystal structure of ROCext represents its in-solution dimeric 
conformation 
 As reported previously, ROCext exists in solution in a dynamic 
monomer-dimer equilibrium. To investigate whether the dimer in 
solution is the same as the dimer in crystal, we introduced an 
intermolecular disulfide bond between two residues that are in close 
proximity of each other, but each residing on opposite side of the 
dimer interface of the crystal dimer. This disulfide bond links in 
trans the helix H2 of one protomer to the helix H4 of the other 
protomer (residues R1398C and W1434C) (Fig. 4a, Fig. S5a, b).  
 The resulting disulfide-stabilized construct (S-S) formed both 
monomeric and dimeric conformations reminiscent of the WT (Fig. 
S6 & S7). Circular dichroism (CD) spectroscopy showed no 
significant structural differences between the S-S mutant and the WT 
dimers (Fig. 4b). However, the S-S dimer loses the ability to convert 
to monomers upon nucleotide binding under disulfide bond-
stabilizing oxidative conditions, but in disulfide bond-breaking 
reducing conditions, its propensity to form monomers is restored to 
the wild-type level (Fig. 4c). Likewise, the S-S dimer is more 
thermostable than the WT under oxidizing conditions, but returned 
 
Figure 3. Comparison with the structure of CtROC. a) Superposition of ROCext dimer (gold 
and red) with CtROC (green), showing that the two structures overlap well, other than the 
turn/loop of the InterSwitch between b1 and b2 (highlighted in grey dashed line). b) 
Superposition of A-chain of ROCext with A-chain of CtROC (6HLU), showing that the two 
structures form dimers via different interactions and surfaces. c) and d) Enlarged view of the 
superposition of ROCext with CtROC, showing the amino acid differences between the 
structures. 
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to WT Tm upon reduction with DTT (Fig. 4d). Finally, the GDP-
binding affinity of the S-S dimer is the same as that of the WT (Fig 
4e).  
 Taken together, these results indicate that the in crystallo dimer is 
structurally the same as the dimer we observed in solution, and 
therefore, insights gleaned from the crystal structure would be 
reflective of the structure in solution. 
 
Insights into the mechanism of ROC  
Understanding the mechanism of the ROC domain of LRRK2 is 
important for understanding its overall function and for the 
development of mechanism-based therapeutic strategies. However, 
the current understanding of ROC has been mostly inferred from 
other well-characterized G-proteins. They all function as molecular 
switches that toggle between "on" and "off" upon binding to GTP or 
GDP, respectively. The binding of GTP typically causes the 
stabilization of two flexible structures, known as Switch I and 
Switch II, as they both interact electrostatically with the γ-phosphate 
of GTP. The ordering of the switch regions presents a surface for 
interacting with downstream effector proteins, and its disordering 
upon GTP hydrolysis (or exchanged for GDP) resets the molecular 
switch back to the "off" state(27-29). Indeed, the ROC domain of 
LRRK2 has been shown to possess some of these characteristics, 
including guanine nucleotide binding, GTP hydrolysis, and 
nucleotide-dependent conformational changes. However, ROC has 
also been shown to present several characteristics that do not fit 
precisely into the typical small G-protein model. For example, ROC 
always exist in tandem with a domain called C-terminal of ROC 
(COR) within a large protein, ROC remains active event when 
mutated to residues that would abolish the activity of the other Ras-
family G-proteins, and its 'ability' to hydrolyze GTP is required for 
its activity but not the hydrolysis event itself per se(30). Although it 
is evident that the ROC domain of LRRK2 is a bona fide G-protein, 
these differences suggest that the mechanism of ROC might be 
different from that of the typical small G-proteins.  
 To gain insights into the mechanism of ROC, we examined the 
atomic structure of ROCext to glean the structural bases for its 
biochemical activities. We recently reported that ROCext exists in a 
dynamic monomer-dimer equilibrium and that GTP or GDP binding 
drives monomerization or dimerization, respectively(15). The 
structure of ROCext reveals that the dimeric configuration of ROCext 
is predominantly stabilized by five hydrogen bonds between β3 in 
the InterSwitch of one protomer and β1 in the core of the other and 
arranged parallel with respect to each other like a zipper (Fig 1b,c). 
The labile nature of these hydrogen bonds is well suited to provide 
the plasticity necessary for the ‘zipping’ and ‘unzipping’ in the 
interconversion between the dimeric and monomeric conformations.  
 Since we have only the GDP-bound structure, how the binding of 
GTP would drive the unzipping of the dimer is unclear. However, 
close examination of our ROCext structure revealed plausible clues. 
The residues flanking either side of the InterSwitch possess dihedral 
angles that are conformationally strained (φ, ψ angles of S1360 and 
Q1411 are -93°, -90° and -105°, 96°, respectively) and, as such, the 
stored energy in these hinge regions could potentially act as a set of 
spring-loaded hinges that provide the driving force for unzipping the 
dimer triggered by GTP binding. This led us to question how does 
GTP binding trigger the process of monomerization. The mechanism 
of GTP-induced conformational changes in small G-proteins 
involves the γ-phosphate group of GTP interacting with a threonine 
residue of Switch I and a glycine residue of Switch II. To investigate 
whether or not this occurs in ROCext, we examined the structure of 
ROCext to see if it consists of the essential γ-phosphate-interacting 
threonine and glycine. To do so, we built a homology model of 
GTP-bound conformation of ROCext by using a GTP-bound 
conformation of Ras (PDB ID: 6Q21) as a modeling template for the 
switch regions. Superposition of 6Q21 with the GTP-bound 
homology model of ROCext reveals that it does indeed consist of a 
threonine residue (T1368) in Switch I and a glycine residue (G1397) 
in Switch II located at practically the same locations as the γ-
 
Figure 4. Engineered disulfide-stabilized ROC dimer. a) A calculated model of ROC dimer consisting of an 
engineered disulfide bond between residues 1398 and 1431 (S-S). b) CD spectrum showing similar profile between the 
S-S dimer and wild-type. c) Size-exclusion chromatography elution profiles showing that the S-S dimer has lost the 
ability to convert to dimer and then regains that capability when the cysteine residues are reduced with DTT. d) 
Thermofluor denaturation assay showing that the S-S dimer is more thermally stable than the wild-type, but reverts to 
wild-type melting temperature when reduced with DTT. e) Fluorescence polarization assay showing that the S-S dimer 
binds GDP with a similar affinity to wild-type.  
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phosphate-interacting residues, T35 and G60, respectively, of Ras 
(Fig. 5a,b and Fig. S8). The conservation of T1368 and G1397, both 
in primary and tertiary structures, with the corresponding γ-
phosphate-interacting residues of Ras suggests that their interaction 
with the γ-phosphate of GTP could analogously trigger 
conformational changes of the Switch regions. We noted that GTP-
binding to Ras triggers the ordering of the Switch I and Switch II; 
however, the structure of ROCext suggests that conformational 
changes in the two switches also necessitate a conformational 
change of the InterSwitch. This opens the possibility that the 
conformational changes of the InterSwitch might be involved in yet 
to be identified interactions analogous to Rab27b interaction with 
Slac2a(23, 24). 
 Biochemical and structural data, shown herein and in the 
literature, have sufficiently demonstrated that the ROC domain of 
LRRK2 forms an independently folded and functional unit; 
however, how it interacts intramolecularly with the other domains, 
especially the adjacent COR domain, remains unclear. To 
investigate this, we docked the dimeric form of ROC as found in our 
crystal structure, the monomer of our crystal structure, and the GTP-
bound model of ROC (ROC-GTP) mentioned above, to the COR 
domain of the CtRoco protein (PDB ID: 6HLU)(18, 19). The crystal 
structure of ROCext showed significant clashes with the docked 
CtRoco COR domain. Even in the monomeric form, the Switch 
regions clashed with the CtRoco COR domain. However, the ROC-
GTP monomeric model docked to the CtRoco COR domain well 
with no backbone clashes between the two domains, and the surface 
containing the Switch regions, especially the InterSwitch, interfaces 
with the COR domain with remarkable complementarity (Fig. 5c,d).  
 Taken together, the data suggest that the Switch regions of the 
ROC domain of LRRK2 interact directly with its COR domain and 
that the nucleotide-dependent conformational changes of the Switch 
regions might modulate this interaction. However, more work is 
needed to validate the insights gleaned from the ROC-COR docking 
exercise. 
 
Insights into the mechanism of disease-associated mutations  
Several lines of evidence have shown that LRRK2 harboring the 
disease-associated mutation R1441C/G caused a reduction in 
GTPase activity(12, 14, 31-33) and GTP binding to the ROC domain 
modulates kinase activity(10, 13, 30). These data suggest that the 
GTPase activity of LRRK2 potentially regulates its kinase activity. 
Recently, we reported that, in addition to a reduction in GTPase 
activity, a common biochemical consequence of all three PD-
associated mutant constructs, including R1441H, R1441G, and 
R1441C, is a loss of the monomer-dimer conformational dynamics 
that we observed in the wild-type protein(15).  
 To gain insights into how the PD-associated mutants led to a loss 
of ROC conformational dynamics, we examined the crystal structure 
of ROCext. The structure revealed that residue R1441 reaches across 
the dimer interface and interacts exquisitely with the opposing 
protomer (Fig. 1 and Fig. 6). The interaction consists of an arginine-
π-stacking between R1441 and F1401. The strong π-stacking 
interaction with the phenyl ring of F1401 orients the plane of the 
R1441 guanidinium moiety such that its two ω-amines are ideally 
positioned for hydrogen-bonding with the backbone carbonyl 
oxygen of F1401 and sidechain hydroxyl of T1404 (Fig. 6b). This 
Arg-Phe π-stacking interaction is typically found in proteins where 
strong and malleable interactions occur(34), thus suggesting that 
residue R1441 might be essential for the stability and plasticity of 
ROC. In addition to the π-stacking, the sidechain of R1441 fits into 
the pocket between residues F1401 and T1404 with perfect Van der 
 
Figure 5. Modeling of a monomeric form of ROC. a) and b) A model of monomeric GTP-bound ROC built based 
on the ROCext dimer and the switch regions of the structure of GppNHp-bound Ras (6q21), showing that ROC has all 
the structural elements and residues that are involved in the GTP-mediated conformational changes in Ras. c) and 
d) docking of GTP-bound ROC model to the COR domain of CtRoco (6HLU), showing the surface complementarity 
between the two structures.  
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Waals complementarity (Fig. S9). Given the intricacy of the 
interactions and the tight complementarity involved, it appeared that 
no other natural amino acid would adequately substitute for the 
arginine at position 1441. To test this, we substituted R1441 for a 
relatively conserved amino acid, lysine, which preserved a 
positively charged amine and a long aliphatic sidechain. We found 
that the R1441K mutant adopted only the monomeric conformation 
and its activity was significantly reduced compared to that of the 
WT (Fig. 6d), suggesting that the intricate interactions conferred by 
the sidechain of residue R1441 is critical for maintaining a 
monomer-dimer equilibrium. This is also consistent with our recent 
report that substituting arginine1441 for a tyrosine resulted in a 
constitutive dimer(15). Now that the structure is available, we can 
see that a Tyr residue at position 1441 could form one hydrogen 
bond and a strong π-π−stacking interaction with phenylalanine 
1401, which would be much less malleable than that of the WT.  
 Taken together, the structure is consistent with all the 
biochemical phenomena we observed in solution and further 
supports that R1441 is uniquely required for the normal nucleotide-
dependent conformational dynamics of ROCext, and suggests that 
the PD-associated mutations at residue R1441 impair this process by 
disrupting the exquisite interactions endowed by the guanidinium 
moiety of the arginine residue.    
 
Conclusion 
Previous knowledge of the structure and function of the ROC 
domain of LRRK2 have been primarily inferred from a homologous 
protein CtRoco due to a lack of LRRK2 protein samples amenable 
for detailed biochemical and biophysical studies. At the onset of our 
investigation into the structure and function of ROC, we were 
uncertain whether the domain in isolation and in the absence of the 
other domains would fold and function independently. However, we 
now know that it does, in both accounts, which has enabled us to 
carry out detailed biochemical and biophysical studies(14-16), as 
well as herein described, to determine its atomic structure. Our 
studies unambiguously demonstrated that ROCext forms an 
independently folded domain that consists of structural features, 
nucleotide binding properties, and enzymatic activity that are 
consistent with all the hallmarks of a Ras-like G-protein. It is 
noteworthy that the structure shows the N- and C-terminus of ROCext 
are in proximity of each other, as they occur in the other Ras-family 
G-proteins, and that they would be unperturbed by the 
conformational changes that occur in the processes of nucleotide 
exchange, hydrolysis activity, and monomer-dimer interconversions; 
therefore, should these activities occur in the full-length LRRK2, 
they can do so without requiring the movement of the flanking 
domains. 
 Although it is theoretically possible for ROC to form a 
homodimer in the context of the full-length LRRK2, it remains 
unclear whether or not that occurs, as there is insufficient data to 
make the determination. On the one hand, electron microscopy (EM) 
showed that full-length LRRK2 is dimeric and that the ROC 
domains are in close proximity for ROC-ROC interactions (although 
the dimeric interface is different from our structure) (35). On the 
other hand, size-exclusion chromatography of a ROC-COR tandem 
construct showed a dimeric structure, but a C-terminally truncated 
ROC-COR domain was mainly monomeric(36). However, the 
nucleotide status of these studies was unclear, and given the fact that 
ROC undergoes nucleotide-dependent conformational changes, the 
question of whether ROC forms a homodimer in the full-length 
LRRK2 remains to be elucidated. Given the fact that LRRK2 is a 
large protein it is likely that, in addition to ROC, the other domains 
are also involved in the dimerization of LRRK2. For example, the 
WD40 domain of LRRK2 forms a strong homodimer(37). 
 Based on the fact that the crystal structure showed that GDP-
bound ROCext is homo-dimeric, SEC-MALS showed that GTP-
bound ROCext is monomeric(15), and the docking models showed 
that ROC might interact with COR via the same surface in the 
homodimer interface, we imagined that homo-dimerization of the 
GDP-bound ROC would exclude its interaction with the COR 
domain and that its monomerization upon GTP binding might 
expose the surfaces available for hetero-dimerization of the two 
domains (Fig. 7).  
 
 
Figure 6. Role of R1441 residue in conformational dynamics of ROC. a) and b) Enlarged 
view of the dimeric interface of ROCext around residue R1441 (rod-bond model). The electron-
density (2FoFc at 1s) is shown as green mesh. c) SEC-MALS of the R1441K mutant form of 
ROC (blue line) compared to the WT dimer (black line) and WT monomer (black dotted line), 
showing that substituting arginine for lysine at position 1441 completely abolished 
dimerization. d) GTPase activity of R1441K (purple and blue) compared to WT (black), 
showing that the R1441K mutation impaired GTPase activity. 
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Methods 
 
A more detailed description of the methods is available in the 
supplemental information. 
 
Protein Expression and Purification 
ROCext consisting of residues 1329-1520 was subcloned into a 
pETDuet-1 vector, expressed in Rosetta2 (DE3) E. coli, and purified 
sequentially with Ni-NTA agarose and Superdex 200 column. The 
disulfide bond-stabilized ROC dimer (S-S) was expressed in 
SHuffle T7 Express lysY E. coli and purified as described for the 
wild-type. 
 
Expression and Purification of Selenomethionine Substituted 
Protein 
SeMet ROCext was expressed from Rosetta2 (DE3) E. coli grown in 
M9 minimal medium containing of a methionine synthesis-
inhibiting cocktail (100 mg of Lys, Phe, Thr (Sigma Aldrich) and 50 
mg of Ile, Leu, Val (Sigma Aldrich)). Expression and purification of 
the SeMet ROCext as described for wild-type ROCext.  
 
Size-Exclusion Chromatography Coupled with Multi-angle Light 
Scattering (SEC-MALS) 
Absolute molecular weight of Rocext in solution we determined by 
multiple-angle light scattering coupled to size-exclusion 
chromatography (SEC-MALS). The setup composes of an AKTA 
FPLC with a size-exclusion column (WTC-030S5, Wyatt 
Technology Corporation), a refractive index detector (Optilab T-
rEX, Wyatt Tech.), and a multiple light scattering detector (Dawn 
HeleosII, Wyatt Tech.). Data processing and analysis were 
performed using the ASTRA software (Wyatt Tech.) 
 
Circular Dichroism Spectroscopy 
CD spectra were collected on a Biologic Science Instruments 
MOS450 AF/CD spectrometer with a slit width of 1.0 mm and data 
acquisition of 1.0 s.  
 
Fluorescence Polarization Nucleotide-binding Assay 
Binding affinity of guanine nucleotides BODIPY-FL-GTPgammaS 
or BODIPY-FL-GDP (Molecular Probes) were determined using 
fluorescence polarization measured by an EnVison 2102 Multilabel 
Plate Reader (Perkin Elmer).  
 
GTPase Activity Assay 
GTPase activity of ROCext was assessed by using the Enzcheck 
assay kit (Invitrogen).  
 
Thermofluor Assay 
Denaturation curves were obtained using a Sypro Orange-based 
method. Samples were heated in the Real-Time PCR Detection 
System (Mastercycler realplex, Eppendorf) from 20 to 85 ℃ and 
fluorescence (550 nm) recorded in increments of 0.4 ℃.  
 
Homology Modeling and Molecular Simulation 
Homology models of the monomeric ROC domain were built based 
on the structures of Ras and C. tepidium Roco (PDB ID: 4Q21, 
6Q21, 3DPU, and 6HLU) by using the program Modeller 9.19 
(Andrej Sali, UCSF). Molecular simulation of the S-S mutant was 
performed using CHARMM(38) and NAMD(39). 
 
Crystallographic data collection and structure determination  
X-ray data was collected at beamline 23-ID-D of the Advanced 
Photon Source and processed with the program HKL2000(40). 
Phases from MR solutions were combined with those from SIRAS 
 
Figure 7. Model of nucleotide-dependent conformational changes of ROC. GDP and GTP 
binding regulates the dynamic interconversions between dimeric and monomeric conformation of 
ROC, respectively. Homo-dimerization of ROC excludes its potential interaction with the COR domain 
and vise versa. Mutations at residue R1441 impair this nucleotide-dependent conformational changes 
and thereby trapping ROC in the monomeric “on” state and potentially bound to the COR domain. 
*R1441H has higher affinity for GTP compared to WT. **R1441G/C/H impair GTP hydrolysis. 
***R1441G/C/H lost the ability to form homo-dimers. 
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with the program Phenix(22). Cycles of rebuilding and refinement 
using the programs Coot(41, 42), Phenix(22), and Refmac(43) at 
Rwork and Rfree of 13.5% and 15.8%, respectively. 
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